Colorectal cancer ranks highly amongst all cancer sites in incidence and contributes to a substantial number of cancer related deaths in the United Kingdom. However, screening of average risk individuals has been shown to reduce both disease associated mortality and incidence. This paper provides an overview of both current and future screening methods for colorectal cancer, as well as current practice for screening in both average and high risk individuals.
Get full access to this article
View all access options for this article.
References
1.
Office of National Statistics.Cancer Statistics Registrations. Registrations of cancer diagnosed in 2002.London: Office for National Statistics, 2005.
2.
StowerMJ, HardcastleJD.The results of 1115 patients with colorectal cancer treated over an eight year period in a single hospital. Eur J Surg Oncol1985; 11: 119–123.
3.
UmplebyHC, BristolJB, RaineyJB.Survival of 727 patients with single carcinomas of the large bowel. Dis Colon Rectum1984; 27: 803–810.
4.
GillPG, MorrisPJ.The survival of patients with colorectal cancer treated in a regional hospital. Br J Surg1978; 65: 17–20.
5.
KievitJ, BruinvelsD.Detection of recurrence after surgery for colorectal cancer. Eur J Cancer1995; 31A; 1222–1225.
6.
ChorostMI, DattaR, SantiagoRC.Colon cancer screening: where have we come from and where do we go?J Surg Oncol2004; 85: 7–13.
7.
CairnsS, ScholefieldJH.Guidelines for colorectal cancer screening in high risk groups. Gut2002; 51(Suppl 5): v1–v2.
8.
GilbertsenVA, McHughR, SchumanL.The earlier detection of colorectal cancers: a preliminary report of the results of the Occult Blood Study. Cancer1980; 45: 2899–2907.
9.
HardcastleJD, ThomasWM, ChamberlainJ.Randomised controlled trial of faecal occult blood screening for colorectal cancer: the results of the first 107,349 subjects. Lancet1989; 1: 1160–64.
10.
PeipensLA, SandlerRS.Epidemiology of colorectal adenomas. Epidemiol Rev1994; 16: 273–297.
11.
WinawerSJ, ZauberAG, HoMN.Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med1993; 328: 1977–1981.
12.
RhodesJM.Colorectal cancer screening in the UK: Joint Position Statement by the British Society of Gastroenterology, The Royal College of Physicians, and the Association of Coloproctology of Great Britain and Ireland. Gut2000; 46: 746–748.
13.
WilsonJMG, JungnerG.Principles and Practice of Screening for Disease.Geneva: WHO, 1968.
14.
FlightIHK, WilsonC, GriffithsL.Interventions for improving uptake of population-based screening for colorectal cancer using fecal occult blood testing. (Protocol)Cochrane Database System Rev2004, Issue 4. Art. No.: CD005035. DOI: 10.1002/14651858.CD005035.
15.
StarkeyBJ.Screening for colorectal cancer. Ann Clin Biochem2002; 39: 351–365.
16.
MacraeFA, St JohnDJ.Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology1982; 82: 891–898.
17.
FeinbergEJ, SteinbergWM, BanksBL.How long to abstain from eating red meat before fecal occult blood tests. Ann Intern Med1990; 113: 403–404.
18.
TörnqvistA, EkelundG, LeandoerL.The value of intensive follow up after curative resection for colorectal carcinoma. Br J Surg1982; 69: 725–728.
19.
GazelleGS, McMahonPM, ScholzFJ.Screening for colorectal cancer. Radiology2000; 215: 327–335.
20.
WinawerSJ, FletcherR, RexD.Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology2003; 124: 544–560.
21.
GreenbergP, BertarioL, GnauckR.A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol2000; 95: 1331–1338.
22.
HewitsonP, GlasziouP, IrwigL.Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database System Rev2007, Issue 1. Art. No.: CD001216. DOI: 10.1002/14651858.CD001216.pub2.
23.
ScholefieldJ, MossH, SufiF.Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut2002; 50: 29–32.
24.
KronborgO, FengerC, OlsenJ.Randomised study of screening for colorectal cancer with faecal occult blood test. Lancet1996; 348: 1467–1471.
25.
JørgensenOD, KronborgO, FengerC.A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut2002; 50: 29–32.
26.
MandelJS, ChurchTR, BondJH.Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med1993; 328: 1365–1371.
27.
MandelJS, ChurchTR, BondJH.The effect of fecal occult blood screening on the incidence of colorectal cancer. N Eng J Med2000; 343: 1603–1607.
28.
MandelJS, ChurchTR, EdererF.Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Nat Cancer Inst1999; 91: 434–437.
29.
KronborgO, JørgensenOD, FengerC.Randomized study of biennial screening with faecal occult blood tests. Results after nine screening rounds. Scand J Gastroenterol2004; 39: 846–851.
30.
SelbyJV, FriedmanJD, QuesenberryCPJr. Effect of fecal occult blood testing on mortality from colorectal cancer. A case control study. Ann Intern Med1993; 118: 1294–1297.
31.
SaitoH, SomaY, KoedaJ.Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case control study. Int J Cancer1995; 61: 465–469.
32.
WahrendorfJ, RobraBP, WiebeltH.Effectiveness of colorectal cancer screening: results from a population-based case-control evaluation in Saarland, Germany. Eur J Cancer Prev1993; 2: 221–227.
33.
LazovichDA, WeissNS, StevensNG.A case control study to evaluate efficacy of screening for fecal occult blood. J Med Screen1995; 2: 84–89.
34.
ZappaM, CastiglioneG, GrazziniG.Effect of faecal occult blood testing on colorectal mortality: results of a population based case control study in the district of Florence, Italy. Int J Cancer1997; 73: 208–210.
VernonSW.Participation in colorectal cancer screening: a review. J Natl Cancer Inst1997; 89: 1406–1422.
37.
UK Colorectal Cancer Screening Pilot Group.Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ2004; 10: 1–5.
38.
MandelJS, BondJH, ChurchTR.Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med1993; 328: 1365–1371.
39.
CravenO.Screening for colorectal cancer using the faecal occult blood test: a critical literature review. Eur J Oncol Nurs2001; 5: 234–243.
40.
RexDK.Current colorectal cancer screening strategies: overview and obstacles to implementation. Rev Gastroenterol Disord2002; 2: S2–S11.
41.
PonceNA, BabeySH, EtzioniDA.Cancer screening in California: Findings from the 2001 California Health Interview Survey. Los Angeles, USA: UCLA Centre for Health Policy Research2003; 38: 536–550.
42.
SubramanianS, KlostermanM, AmonkarMM.Adherence with colorectal cancer screening guidelines: a review. Prev Med2004; 38: 536–550.
43.
ScholefieldJ.ABC of colorectal cancer. BMJ2000; 321: 1004–1006.
44.
NewcombPA, NorfleetRG, StorerBE.Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst1992; 84: 1572–1575.
45.
MullerAD, SonnenbergA.Protection by endoscopy against death from colorectal cancer. A case control study amongst veterans. Arch Intern Med1995; 155: 1741–1748.
46.
DevesaSS, ChowWH.Variation in colorectal cancer incidence in the United States by subsite of origin. Cancer1993; 71: 3819–3826.
47.
SelbyJV, FriedmanGD.US Preventive Task Force. Sigmoidoscopy in the periodic health examination of symptomatic adults. JAMA1989; 261: 594–601.
48.
LiebermanDA, WeissDG, BondJH.Use of colonoscopy to screen asymptomatic adults for colorectal cancer. New Engl J Med2000; 343: 162–168.
49.
WinawerSJ, ZauberAG, HoMN.Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. New Engl J Med1993; 329: 1977–1981.
50.
CitardaF, TomaselliG, CapocacciaR.Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut2001; 48: 812–815.
51.
RexDK, CutlerCS, LemmelGT.Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology1997; 112: 24–28.
52.
RexDK, RhahmaniEY, HasemanJH.Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology1997; 112: 17–23.
53.
GattoNM, FruchtH, SundararajanV.Risk of perforation after colonoscopy and sigmoidoscopy: a population based study. J Natl Cancer Institute2003; 95: 230–236.
54.
JohnsonCD, DachmanAH.CT colonography: the next colon screening examination?Radiology2000; 216: 331–341.
55.
LevinB, BrooksD, SmithR.Emerging technologies in screening for colorectal cancer: CT colonography, immunological fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin2003; 53: 44–45.
56.
NicholsonFB, BarroFJ, BertramCI.The role of CT colonography in colorectal cancer screening. Am J Gastroenterol2005; 100: 2315–2323.
57.
JohnsonCD, HarmsenWS, WilsonLA.Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps. Gastroenterology2003; 125: 311–319.
58.
PickhardtPJ, ChoiJR, HwangI.Computed tomographic virtual colonography to screen for colorectal neoplasia in asymptomatic adults. N Eng J Med2003; 349: 2191–2200.
59.
CottonPB, DurkalskiVL, PineauBC.Computed tomographic virtual colonography: a multicentre comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA2004; 291: 1713–1719.
60.
RockeyD, PaulsonE, NiedzwieckiD.Analysis of air contrast barium enema, computed tomographic colonography and colonoscopy: prospective comparison. Lancet2005; 365: 305–311.
61.
EideTJ.Natural history of adenomas. World J Surg1991; 15: 3–6.
62.
GlueckerTM, JohnsonCD, WilsonLA.Extracolonic findings at CT colonography: evaluation of prevalence and cost in a screening population. Gastroenterology2003; 124: 911–916.
HoffG, GrotmolJ, Thiis-EvensenE.Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut2004; 53: 1329–1333.
65.
MoranA, RadleyS, NeoptolemosJ.Detection of colorectal cancer by faecal α1-antitrypsin. Ann Clin Biochem1993; 30: 28–33.
66.
NakayamaT, YasuokaH, KishinoT.ELISA for occult faecal albumin. Lancet1987; 1: 1368–1369.
67.
MüllerAD, SonnenbergA.Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case control study of 32,702 veterans. Ann Intern Med1995; 123: 904–910.
68.
NewcombPA, StorerBE, MorimotoLM.Long term efficacy of flexible sigmoidoscopy in the reduction of colorectal cancer. J Nat Cancer Inst2003; 95: 622–625.
69.
PickhardtPJ, ChoiJR, HwangI.Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic individuals. N Engl J Med2003; 349: 2191–2200.
70.
LuboldtW, MannC, TryonSL.Computer aided diagnosis in contrast enhanced CT colonography: an approach based on contrast. Eur Radiol2002; 12: 2236–2241.
71.
AhlquistDA, McGillDB, SchwartzS.Fecal blood levels in health and disease. A study using HemoQuant. N Engl J Med1985; 312: 1422–1428.
72.
YoungGP.Selecting an occult blood test for use as a screening tool for large bowel cancer. Front Gastrointestin Res1991; 18: 135–156.
73.
LevinB, SmithRA, FeldmanGE.Promoting early detection tests for colorectal carcinoma and adenomatous polyps: a framework for action. The strategic plan for the National Colorectal Cancer Roundtable. Cancer2002; 95: 1618–1628.
74.
EadenJA, MayberryJF.Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut2002; 51(Suppl 5): v10–v12.
Lennard JonesJE, ConnellWR.Surveillance: Irritable Bowel Disease. In CohenAM, WinawerS (eds) Cancer of the Colon, Rectum and Anus, NY: McGraw-Hill, 1995. pp 350–370.
77.
BondJH.Colorectal cancer update. Prevention, screening, treatment, and surveillance for high risk groups. Med Clin North Am2000; 84: 1163–1182.
78.
DunlopMG.Guidance on large bowel surveillance for people with two first degree relatives with colorectal cancer or one first degree relative diagnosed with colorectal cancer under 45 years. Gut2002; 51(Suppl 5): v17–v20.
79.
GuillemJG, FordeKA, TreatMR.Colonoscopic screening for neoplasms in asymptomatic first degree relatives of colon cancer patients: a controlled prospective study. Dis Colon Rectum1992; 35: 523–529.
80.
GagliaP, AtkinWS, WhitelawS.Variables associated with the risk of colorectal adenomas in asymptomatic individuals with a family history of colorectal cancer. Gut1995; 36: 385–390.
81.
VasenHF, TaalBG, NagengastFM.Hereditary nonpolyposis colorectal cancer: results from a long term surveillance in 50 families. Eur J Cacner1995; 31A: 1145–1148.
BusseyHJR.Family Polyposis Coli: Family Studies, Histopathology, Differential Diagnosis and the Results of Treatment.Baltimore: John Hopkins University Press.1975.
SuLK, KohlmannW PA.Different familial adenomatous polyposis phenotypes resulting from deletions of the entire APC exon 15. Hum Genet2002; 11: 88–95.
86.
BurtR, NeklasonDW.Genetic testing for inherited colon cancer. Gastroenterology2005; 128: 1696–1796.
87.
British Society for Gastroenterology.Summary of recommendations for colorectal cancer screening and surveillance in high risk groups. Gut2002; 51(Suppl 5): v28.
88.
ScholefieldJH, SteeleRJC.Guidelines for follow up after resection for colorectal cancer. Gut2002; 51(Suppl 5): v3–v5.
89.
BradyPG, StrakerPJ, GoldschmidS.Surveillance colonoscopy after resection for colon carcinoma. South Med J1990; 83: 765–768.
